JPS6324996B2 - - Google Patents

Info

Publication number
JPS6324996B2
JPS6324996B2 JP54107307A JP10730779A JPS6324996B2 JP S6324996 B2 JPS6324996 B2 JP S6324996B2 JP 54107307 A JP54107307 A JP 54107307A JP 10730779 A JP10730779 A JP 10730779A JP S6324996 B2 JPS6324996 B2 JP S6324996B2
Authority
JP
Japan
Prior art keywords
group
carbon atoms
methyl
phenyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54107307A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5533479A (en
Inventor
Ausuteru Fuorukuharuto
Haidaa Yoahimu
Eberurain Uorufugangu
Deiederen Uirii
Haaruman Barutaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of JPS5533479A publication Critical patent/JPS5533479A/ja
Publication of JPS6324996B2 publication Critical patent/JPS6324996B2/ja
Granted legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F8/00—Arrangements for software engineering
    • G06F8/30—Creation or generation of source code
    • G06F8/31—Programming languages or programming paradigms
    • G06F8/313—Logic programming, e.g. PROLOG programming language
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Software Systems (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Computing Systems (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP10730779A 1978-08-25 1979-08-24 Novel benzimidazole Granted JPS5533479A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782837161 DE2837161A1 (de) 1978-08-25 1978-08-25 Neue benzimidazole und deren verwendung

Publications (2)

Publication Number Publication Date
JPS5533479A JPS5533479A (en) 1980-03-08
JPS6324996B2 true JPS6324996B2 (enrdf_load_stackoverflow) 1988-05-23

Family

ID=6047905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10730779A Granted JPS5533479A (en) 1978-08-25 1979-08-24 Novel benzimidazole

Country Status (3)

Country Link
JP (1) JPS5533479A (enrdf_load_stackoverflow)
DE (1) DE2837161A1 (enrdf_load_stackoverflow)
ZA (1) ZA794472B (enrdf_load_stackoverflow)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3505609A1 (de) * 1985-02-19 1986-08-21 Merck Patent Gmbh, 6100 Darmstadt Benzimidazolyl-pyridazinone
DE3804490A1 (de) * 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3805635A1 (de) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
DE3814057A1 (de) * 1988-04-26 1989-11-09 Heumann Pharma Gmbh & Co 6-oxo-pyridazinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3913597A1 (de) * 1989-04-25 1990-11-08 Heumann Pharma Gmbh & Co Diazinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4001622A1 (de) * 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP4714921B2 (ja) * 2005-02-14 2011-07-06 トーアエイヨー株式会社 ピモベンダンの製造法及びその中間体
MX2008002166A (es) * 2005-08-15 2008-04-22 Irm Llc Compuestos y composiciones como mimeticos de trombopoietina (tpo).
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Also Published As

Publication number Publication date
DE2837161A1 (de) 1980-03-06
JPS5533479A (en) 1980-03-08
ZA794472B (en) 1981-04-29

Similar Documents

Publication Publication Date Title
FI66372C (fi) Foerfarande foer framstaellning av farmakologiskt verkande i 5- eller 6-staellning med en pyridazinonring substituerade besimidazoler
JPS6324996B2 (enrdf_load_stackoverflow)
FI59408B (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla bensimidazoler
Combs et al. Heteroatom analogs of bemoradan: chemistry and cardiotonic activity of 1, 4-benzothiazinylpyridazinones
AU2003203148A1 (en) Novel aryl- and heteroarylpiperazines
JP2002507611A (ja) イミダゾロン食欲抑制薬：ｉｉ．フェニル誘導体
EP0263352A1 (de) Neue Imidazo-benzoxazinone, ihre Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0275997A1 (en) 3(2H)pyridazinone, process for its preparation and antagonistic agent against SRS-A containing it
JPS6136282A (ja) 窒素を含む複素環式化合物からなる医薬品とその製造方法
JP2000511534A (ja) ベンゾオキサジノンドーパミンｄ４受容体アンタゴニスト
JP6755950B2 (ja) ラクタム化合物誘導体およびその応用
US5151420A (en) Substituted pyridazinones
SU581866A3 (ru) Способ получени проивзодных бензимидазола или их солей
KR910003153B1 (ko) 7-피페리디노-1,2,3,5-테트라하이드로이미다조[2,1-b]퀴나졸린-2-온의 제조방법
JPS6330911B2 (enrdf_load_stackoverflow)
JPH02145584A (ja) クロマン誘導体
JPH0129190B2 (enrdf_load_stackoverflow)
HU181000B (en) Process for preparing substituted 7,7-dimethyl-5h,7h-imidazo/4,5-h/-isoquinoline-4,6-diones
US4831032A (en) Cardiotonic benzimidazoles
JPH0365349B2 (enrdf_load_stackoverflow)
HU196758B (en) Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them
NO874780L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolo-benzimidazol-derivater.
JPH09124631A (ja) ベンゾフラン誘導体及びそれを含む医薬組成物
KR790001578B1 (ko) 벤즈이미다졸류의 제조 방법
DE2922336A1 (de) Neue in 5- oder 6-stellung durch einen pyridazinonring substituierte benzimidazole und deren verwendung als arzneimittel

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term